https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/NTHI/neonc-abudhabi-research-brain-cancer BiopharmaWatch en 2026-10-21T13:35:00.000Z NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward https://www.biopharmawatch.com/news/ILMN/illumina-bioinsight-platform-new-software-accelerate-discovery BiopharmaWatch en 2026-10-21T13:15:00.000Z Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery https://www.biopharmawatch.com/news/LIVN/livanova-presents-november-healthcare-conferences BiopharmaWatch en 2026-10-21T13:00:00.000Z LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November https://www.biopharmawatch.com/news/EW/fda-approval-edwards-lifesciences-pascal-precision-system BiopharmaWatch en 2026-10-21T13:00:00.000Z FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-new-clinical-data-multiple-sclerosis BiopharmaWatch en 2026-10-21T12:52:00.000Z TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026 https://www.biopharmawatch.com/news/SMMT/akeso-summit-therapeutics-ivonescimab-trial-collaboration BiopharmaWatch en 2026-10-21T12:42:00.000Z Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer https://www.biopharmawatch.com/news/MRK/merck-nvidia-microsoft-dawn-health-rare-tumors BiopharmaWatch en 2026-10-21T12:35:00.000Z Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors https://www.biopharmawatch.com/news/BEAT/headstart-acs-completes-enrollment-heartbeam-technology BiopharmaWatch en 2026-10-21T12:31:00.000Z HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology https://www.biopharmawatch.com/news/HCA/hca-healthcare-crush-the-crisis-drug-take-back BiopharmaWatch en 2026-10-21T12:30:00.000Z HCA Healthcare to Host Eighth Annual “Crush the Crisis” National Prescription Drug Take Back Day https://www.biopharmawatch.com/news/ANGO/angiodynamics-direct-study-results-cpt-code-ire BiopharmaWatch en 2026-10-21T12:30:00.000Z AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE https://www.biopharmawatch.com/news/EOLS/evolus-third-quarter-financial-results-november-2026 BiopharmaWatch en 2026-10-21T12:30:00.000Z Evolus to Report Third Quarter Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/SDGR/schrodinger-announces-q3-2026-results-date BiopharmaWatch en 2026-10-21T12:30:00.000Z Schrödinger to Announce Third Quarter 2026 Financial Results on November 4 https://www.biopharmawatch.com/news/PLUR/pluri-chairman-investor-acquire-eib-loan BiopharmaWatch en 2026-10-21T12:30:00.000Z Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the Company https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-results-chest-2026 BiopharmaWatch en 2026-10-21T12:30:00.000Z Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026 https://www.biopharmawatch.com/news/HSCS/heartsciences-proxy-statement-fortitude-mining-combination BiopharmaWatch en 2026-10-21T12:30:00.000Z HeartSciences Files Definitive Proxy Statement for Proposed Business Combination with Fortitude Mining https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-sotagliflozin-cardiovascular-research BiopharmaWatch en 2026-10-21T12:30:00.000Z Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease https://www.biopharmawatch.com/news/STIM/neuronetics-q3-2026-results-conference-call BiopharmaWatch en 2026-10-21T12:30:00.000Z Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call https://www.biopharmawatch.com/news/PRGO/perrigo-q3-2026-financial-results-release BiopharmaWatch en 2026-10-21T12:30:00.000Z Perrigo to Release Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/HIMS/hims-expands-testosterone-care-launch-trt BiopharmaWatch en 2026-10-21T12:20:00.000Z Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men’s Health Launch to Date https://www.biopharmawatch.com/news/IMNN/imunon-sale-thermodox-vectordox BiopharmaWatch en 2026-10-21T12:15:00.000Z IMUNON Announces Strategic Sale of ThermoDox® https://www.biopharmawatch.com/news/VIVS/vivosim-labs-namkind-platform-expansion BiopharmaWatch en 2026-10-21T12:05:00.000Z VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling https://www.biopharmawatch.com/news/LABT/lakewood-amendex-nu3-antimicrobial-idweek-2026 BiopharmaWatch en 2026-10-21T12:02:00.000Z Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026 https://www.biopharmawatch.com/news/HYFT/mindwalk-screens-antibody-sequences-immune-risk BiopharmaWatch en 2026-10-21T12:01:00.000Z MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours https://www.biopharmawatch.com/news/ACXP/acurx-publishes-study-dna-pol-iiic-inhibitors BiopharmaWatch en 2026-10-21T12:01:00.000Z Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect https://www.biopharmawatch.com/news/VYGR/voyager-ceo-succession-plan-robin-swartz BiopharmaWatch en 2026-10-21T12:01:00.000Z Voyager Announces CEO Succession Plan, Appoints Robin Swartz President https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-positive-admet-results BiopharmaWatch en 2026-10-21T12:00:00.000Z Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies https://www.biopharmawatch.com/news/AHCO/adapthealth-q3-2026-earnings-release-date BiopharmaWatch en 2026-10-21T12:00:00.000Z AdaptHealth Corp. Announces Third Quarter 2026 Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/MCK/mckesson-quarterly-dividend-declared BiopharmaWatch en 2026-10-21T12:00:00.000Z McKesson Corporation Declares Quarterly Dividend https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-termination-purchase-right BiopharmaWatch en 2026-10-21T12:00:00.000Z China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right https://www.biopharmawatch.com/news/HKPD/cellyan-biotechnology-reverse-stock-split BiopharmaWatch en 2026-10-21T12:00:00.000Z Cellyan Biotechnology Announces a 1-for-20 Reverse Stock Split https://www.biopharmawatch.com/news/MENS/jyong-biotech-investor-events-silicon-valley-irvine BiopharmaWatch en 2026-10-21T12:00:00.000Z Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California https://www.biopharmawatch.com/news/ECOR/electrocore-present-planet-microcap-toronto-2026 BiopharmaWatch en 2026-10-21T12:00:00.000Z electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub https://www.biopharmawatch.com/news/APYX/apyx-medical-investor-conferences-2026 BiopharmaWatch en 2026-10-21T12:00:00.000Z Apyx Medical Corporation to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AMRN/amarin-q3-2026-financial-results-conference-call BiopharmaWatch en 2026-10-21T12:00:00.000Z Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026 https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-10-21T12:00:00.000Z Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 https://www.biopharmawatch.com/news/COLL/collegium-present-research-adult-pediatric-adhd BiopharmaWatch en 2026-10-21T12:00:00.000Z Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses https://www.biopharmawatch.com/news/GERN/geron-q3-2026-financial-results-announcement BiopharmaWatch en 2026-10-21T12:00:00.000Z Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/PYPD/polypid-d-plex1800-idweek-2026-presentation BiopharmaWatch en 2026-10-21T12:00:00.000Z PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026 https://www.biopharmawatch.com/news/STRO/sutro-biopharma-stro-006-phase-1-trial BiopharmaWatch en 2026-10-21T12:00:00.000Z Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-expands-investor-outreach-dubai BiopharmaWatch en 2026-10-21T12:00:00.000Z Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai https://www.biopharmawatch.com/news/ABT/abbott-reports-q3-2026-results-eps-guidance BiopharmaWatch en 2026-10-21T11:34:15.086Z Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance https://www.biopharmawatch.com/news/USPH/us-physical-therapy-q3-2026-earnings-release BiopharmaWatch en 2026-10-21T11:30:00.000Z U.S. Physical Therapy, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call Dates https://www.biopharmawatch.com/news/IBRX/immunitybio-database-lock-quilt-2-005-trial BiopharmaWatch en 2026-10-21T11:30:00.000Z ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer https://www.biopharmawatch.com/news/ZLAB/zai-lab-q3-2026-results-announcement BiopharmaWatch en 2026-10-21T11:30:00.000Z Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026 https://www.biopharmawatch.com/news/ELV/elevance-health-names-jeff-park-president-carelon BiopharmaWatch en 2026-10-21T11:30:00.000Z Elevance Health Names Jeff Park President of Carelon https://www.biopharmawatch.com/news/COR/cencora-acquire-american-oncology-network BiopharmaWatch en 2026-10-21T11:30:00.000Z Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology https://www.biopharmawatch.com/news/CNSY/cerenome-reyobiq-dual-mechanism-cancer BiopharmaWatch en 2026-10-21T11:30:00.000Z Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™ https://www.biopharmawatch.com/news/ABT/abbott-separates-nutrition-business-into-independent-company BiopharmaWatch en 2026-10-21T11:25:00.000Z Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company https://www.biopharmawatch.com/news/INMB/inmune-bio-ebstrocel-uk-approval-2027 BiopharmaWatch en 2026-10-21T11:15:00.000Z INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027 https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-miv-cel-sps-data-ms-toronto BiopharmaWatch en 2026-10-21T11:15:00.000Z Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-fda-acceptance-oxylanthanum-carbonate BiopharmaWatch en 2026-10-21T11:05:00.000Z Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027 https://www.biopharmawatch.com/news/IVVD/invivyd-vms063-monoclonal-antibody-measles-idweek-2026 BiopharmaWatch en 2026-10-21T11:01:00.000Z Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026 https://www.biopharmawatch.com/news/TLSA/tiziana-management-team-actrims-ectrims-meeting-toronto BiopharmaWatch en 2026-10-21T11:00:00.000Z Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-q3-results-2027-growth BiopharmaWatch en 2026-10-21T11:00:00.000Z Healthcare Services Group Reports Third Quarter Results https://www.biopharmawatch.com/news/UTHR/united-therapeutics-q3-2026-results-report BiopharmaWatch en 2026-10-21T11:00:00.000Z United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026 https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-phase-2-epetraborole-polycythemia-vera BiopharmaWatch en 2026-10-21T11:00:00.000Z AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms https://www.biopharmawatch.com/news/IMUX/immunic-vidofludimus-calcium-mst2026 BiopharmaWatch en 2026-10-21T11:00:00.000Z Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting https://www.biopharmawatch.com/news/GNPX/genprex-tusc2-role-brain-aging BiopharmaWatch en 2026-10-21T11:00:00.000Z Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-nasdaq-compliance-october-2026 BiopharmaWatch en 2026-10-21T11:00:00.000Z Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard https://www.biopharmawatch.com/news/INMB/inmune-bio-global-commercialization-framework-ebstrocel BiopharmaWatch en 2026-10-21T11:00:00.000Z INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar https://www.biopharmawatch.com/news/TLRY/west-ham-brewdog-boleyn-brew-launch BiopharmaWatch en 2026-10-21T11:00:00.000Z West Ham United F.C. and BrewDog Unveil Boleyn Brew: A Fan-Created Matchday Beer Made by Hammers, for Hammers https://www.biopharmawatch.com/news/ROIV/roivant-financial-results-business-update-november-2026 BiopharmaWatch en 2026-10-21T11:00:00.000Z Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 https://www.biopharmawatch.com/news/IRD/opus-genetics-fda-clearance-opgx-rdh12-gene-therapy BiopharmaWatch en 2026-10-21T11:00:00.000Z Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness https://www.biopharmawatch.com/news/SHC/sotera-health-third-quarter-2026-earnings-release BiopharmaWatch en 2026-10-21T11:00:00.000Z Sotera Health Announces Third-Quarter 2026 Earnings Release Date https://www.biopharmawatch.com/news/JBIO/jade-biosciences-highlight-advancement-jade101-asn-kidney-week-2026 BiopharmaWatch en 2026-10-21T11:00:00.000Z Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026 https://www.biopharmawatch.com/news/PBM/psyence-biomed-completes-psylabs-investment BiopharmaWatch en 2026-10-21T11:00:00.000Z Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-appoints-linea-aspesi-cpo BiopharmaWatch en 2026-10-21T11:00:00.000Z Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer https://www.biopharmawatch.com/news/BCRX/biocryst-fda-approval-orladeyo-150mg-pellets BiopharmaWatch en 2026-10-21T11:00:00.000Z BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE https://www.biopharmawatch.com/news/IMVT/immunovant-financial-results-business-update-november-2026 BiopharmaWatch en 2026-10-21T11:00:00.000Z Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 https://www.biopharmawatch.com/news/ROIV/roivant-priovant-brepocitinib-results-clarity-trials BiopharmaWatch en 2026-10-21T11:00:00.000Z Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) https://www.biopharmawatch.com/news/MSLE/satellos-participate-upcoming-investor-conferences BiopharmaWatch en 2026-10-21T11:00:00.000Z Satellos to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/LH/labcorp-declares-quarterly-dividend-20261021 BiopharmaWatch en 2026-10-21T10:50:00.000Z Labcorp Declares Quarterly Dividend https://www.biopharmawatch.com/news/MRK/european-commission-approves-keytruda-padcev-mibc BiopharmaWatch en 2026-10-21T10:45:00.000Z European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-ivonescimab-biliary-tract-cancer-trial BiopharmaWatch en 2026-10-21T10:05:00.000Z Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer https://www.biopharmawatch.com/news/ELV/elevance-health-reports-q3-2026-results BiopharmaWatch en 2026-10-21T10:00:00.000Z Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance https://www.biopharmawatch.com/news/PSNL/personalis-next-personal-data-esmo-2026 BiopharmaWatch en 2026-10-21T10:00:00.000Z Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026 https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-q3-2026-results BiopharmaWatch en 2026-10-21T10:00:00.000Z Thermo Fisher Scientific Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/DHR/danaher-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-21T10:00:00.000Z Danaher Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-q3-2026-results BiopharmaWatch en 2026-10-21T10:00:00.000Z Integra LifeSciences Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/blog/phase-2-3-readouts-week-of-2026-10-19 BiopharmaWatch en 2026-10-21T07:15:22.695Z MN-166 in ALS: Phase 2 and 3 Readouts Oct 19, 2026 https://www.biopharmawatch.com/news/IPHA/innate-pharma-participate-stifel-jefferies-conference BiopharmaWatch en 2026-10-21T05:00:00.000Z Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/TKNO/teknova-pricing-40-million-public-offering BiopharmaWatch en 2026-10-21T02:30:00.000Z Teknova Announces Pricing of $40 Million Public Offering of Common Stock https://www.biopharmawatch.com/news/IONS/gsk-approves-hibsago-bepirovirsen-chronic-hepatitis-b BiopharmaWatch en 2026-10-21T01:20:00.000Z Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB) https://www.biopharmawatch.com/news/IRON/disc-medicine-pricing-450-million-offering BiopharmaWatch en 2026-10-21T00:52:00.000Z Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock https://www.biopharmawatch.com/news/HCM/hutchmed-kras-egfr-antibody-conjugate-license-gsk BiopharmaWatch en 2026-10-21T00:00:00.000Z HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China https://www.biopharmawatch.com/news/GSK/hibsago-bepirovirsen-approval-chronic-hepatitis-b BiopharmaWatch en 2026-10-20T23:58:00.000Z Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB) https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-lisaftoclax-breakthrough-therapy-designation BiopharmaWatch en 2026-10-20T23:30:29.000Z Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL https://www.biopharmawatch.com/news/TLX/telix-reports-q3-2026-financial-performance BiopharmaWatch en 2026-10-20T22:10:00.000Z Telix Reports Third Quarter 2026 Financial Performance https://www.biopharmawatch.com/blog/top-pharma-companies-by-revenue-2025 BiopharmaWatch en 2026-10-20T21:37:19.669Z Top Pharma Companies by Revenue in 2025, Drug by Drug https://www.biopharmawatch.com/news/RNA/atrium-therapeutics-inducement-grants-nasdaq BiopharmaWatch en 2026-10-20T21:23:00.000Z Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/blog/fda-calendar-q4-2026-key-pdufa-dates-upcoming-approvals BiopharmaWatch en 2026-10-20T21:02:14.537Z FDA Calendar Q4 2026: Key PDUFA Dates and Upcoming Approvals https://www.biopharmawatch.com/news/SRZN/surrozen-closes-second-tranche-private-placement BiopharmaWatch en 2026-10-20T20:59:00.000Z Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million https://www.biopharmawatch.com/news/ZTS/zoetis-fda-approval-convenia-rtu-dogs BiopharmaWatch en 2026-10-20T20:42:00.000Z Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment https://www.biopharmawatch.com/news/ALC/alcon-acquires-neurotech-and-encelto-fda-approval BiopharmaWatch en 2026-10-20T20:35:00.000Z Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2 https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-q3-2026-financial-results-call BiopharmaWatch en 2026-10-20T20:32:00.000Z TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call https://www.biopharmawatch.com/news/STVN/stevanato-group-q3-2026-results-release BiopharmaWatch en 2026-10-20T20:30:00.000Z Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/STE/steris-conference-call-fiscal-2027-q2 BiopharmaWatch en 2026-10-20T20:30:00.000Z STERIS to Host a Conference Call for Fiscal 2027 Second Quarter on November 5, 2026 https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-pda-conference-2026 BiopharmaWatch en 2026-10-20T20:25:00.000Z Rapid Micro Biosystems to Participate at the PDA Pharmaceutical Microbiology Conference 2026 https://www.biopharmawatch.com/news/NBTX/voting-rights-shares-capital-company-20261020 BiopharmaWatch en 2026-10-20T20:15:07.000Z Voting Rights and Shares Capital of the Company https://www.biopharmawatch.com/news/AMGN/amgen-presents-esmo-2026 BiopharmaWatch en 2026-10-20T20:15:00.000Z AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026 https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-q3-2026-conference-call BiopharmaWatch en 2026-10-20T20:15:00.000Z Dentsply Sirona to Host Third Quarter 2026 Conference Call on November 5 https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-10-20T20:13:00.000Z AN2 Therapeutics to Participate at Upcoming Investor Conferences https://www.biopharmawatch.com/news/RCEL/avita-medical-q3-2026-financial-results BiopharmaWatch en 2026-10-20T20:10:00.000Z AVITA Medical to Announce Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KRMD/koru-medical-q3-2026-financial-results-report BiopharmaWatch en 2026-10-20T20:05:00.000Z KORU Medical Systems to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/VRTX/vertex-appoints-daniel-brennan-board-directors BiopharmaWatch en 2026-10-20T20:05:00.000Z Vertex Appoints Daniel Brennan to its Board of Directors https://www.biopharmawatch.com/news/INO/inovio-favorable-judgment-vgxi-geneone BiopharmaWatch en 2026-10-20T20:05:00.000Z INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science https://www.biopharmawatch.com/news/ILMN/illumina-webcast-upcoming-investor-conference-20261020 BiopharmaWatch en 2026-10-20T20:05:00.000Z Illumina To Webcast Upcoming Investor Conference https://www.biopharmawatch.com/news/LFMD/lifemd-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-20T20:05:00.000Z LifeMD to Report Third Quarter 2026 Financial Results on November 9 https://www.biopharmawatch.com/news/ISRG/intuitive-announces-third-quarter-earnings-20261020 BiopharmaWatch en 2026-10-20T20:05:00.000Z Intuitive Announces Third Quarter Earnings https://www.biopharmawatch.com/news/RXST/rxsight-q3-2026-financial-results-report BiopharmaWatch en 2026-10-20T20:05:00.000Z RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3 https://www.biopharmawatch.com/news/CBLL/ceribell-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-20T20:05:00.000Z Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/TKNO/teknova-announces-public-offering-common-stock BiopharmaWatch en 2026-10-20T20:02:00.000Z Teknova Announces Proposed Public Offering of Common Stock https://www.biopharmawatch.com/news/BRKR/bruker-q3-2026-earnings-release-webcast BiopharmaWatch en 2026-10-20T20:01:00.000Z Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-appoints-scott-wasserman BiopharmaWatch en 2026-10-20T20:01:00.000Z Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors https://www.biopharmawatch.com/news/TKNO/teknova-preliminary-q3-2026-financial-results BiopharmaWatch en 2026-10-20T20:01:00.000Z Teknova Announces Preliminary Third Quarter Financial Results https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-q3-2026-results-report BiopharmaWatch en 2026-10-20T20:00:00.000Z Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/CORT/2026-ada-easd-consensus-report-hypercortisolism-screening BiopharmaWatch en 2026-10-20T20:00:00.000Z 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes https://www.biopharmawatch.com/news/ALKS/alkermes-third-quarter-financial-results-november-2026 BiopharmaWatch en 2026-10-20T20:00:00.000Z Alkermes to Report Third Quarter Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/AVXL/anavex-corporate-update-blarcamesine-studies BiopharmaWatch en 2026-10-20T20:00:00.000Z Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies https://www.biopharmawatch.com/news/ENSG/ensign-group-investor-action-notice BiopharmaWatch en 2026-10-20T19:38:00.000Z INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in The Ensign Group, Inc. (NASDAQ: ENSG) to Contact Law Firm https://www.biopharmawatch.com/news/GEHC/ge-healthcare-global-collaborations-theranostics-imaging BiopharmaWatch en 2026-10-20T16:39:00.000Z GE HealthCare announces five new global collaborations to advance the next generation of theranostics imaging https://www.biopharmawatch.com/news/RKTO/rocket-one-ai-chip-development-agreement BiopharmaWatch en 2026-10-20T14:40:53.000Z Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing https://www.biopharmawatch.com/news/ONCY/oncolytics-reo-033-trial-esmo-2026 BiopharmaWatch en 2026-10-20T13:35:00.000Z Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer https://www.biopharmawatch.com/news/NTHI/neonc-technologies-catalyst-season-fda-meeting BiopharmaWatch en 2026-10-20T13:33:00.000Z Forget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst Season https://www.biopharmawatch.com/news/ELOX/eloxx-phase-2-express-study-design-adpkd BiopharmaWatch en 2026-10-20T13:31:00.000Z Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer https://www.biopharmawatch.com/news/HCTI/hcti-expands-ai-business-new-contracts-revenue BiopharmaWatch en 2026-10-20T13:20:00.000Z HCTI Expands AI Business with 6 New Contracts, Targeting approx. $4.65M in Annual Run Rate Revenue https://www.biopharmawatch.com/news/CODX/comira-diagnostics-nuwatin-2026-forum-participation BiopharmaWatch en 2026-10-20T13:15:00.000Z Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum https://www.biopharmawatch.com/news/CELZ/creative-medical-ultrasome-knee-osteoarthritis-study BiopharmaWatch en 2026-10-20T13:15:00.000Z Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study https://www.biopharmawatch.com/news/SNY/scionxbio-sanofi-collaboration-xrna-therapeutics BiopharmaWatch en 2026-10-20T13:10:00.000Z ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics https://www.biopharmawatch.com/news/GH/guardant-health-liquid-biopsy-esmo-congress-2026 BiopharmaWatch en 2026-10-20T13:02:00.000Z Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026 https://www.biopharmawatch.com/news/CVS/minuteclinic-opens-new-clinics-massachusetts BiopharmaWatch en 2026-10-20T13:00:00.000Z MinuteClinic® opens three new retail medical clinics to serve Massachusetts patients https://www.biopharmawatch.com/news/PEN/penumbra-cavt-technology-fda-clearance-dvt BiopharmaWatch en 2026-10-20T13:00:00.000Z Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT) https://www.biopharmawatch.com/news/AMGN/tezspire-eosinophilic-esophagitis-trial-results BiopharmaWatch en 2026-10-20T13:00:00.000Z TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS https://www.biopharmawatch.com/news/OMDA/omada-health-glp-1-care-track-research-presentation BiopharmaWatch en 2026-10-20T13:00:00.000Z Omada Health to Present Peer-Reviewed Research on Improving Weight Loss and Body Composition During GLP-1 Treatment at World Obesity and Weight Management Congress https://www.biopharmawatch.com/news/FEMY/femasys-sandsrx-partnership-femaseed-launch BiopharmaWatch en 2026-10-20T13:00:00.000Z Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs https://www.biopharmawatch.com/news/SCNI/scinai-ceo-shareholder-update-cdmo-growth BiopharmaWatch en 2026-10-20T12:49:00.000Z Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-launches-tru-niagen-skincare BiopharmaWatch en 2026-10-20T12:32:00.000Z Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product https://www.biopharmawatch.com/news/ACRV/acrivon-advances-acr-7280-cdk11-inhibitor-ind-filing-2027 BiopharmaWatch en 2026-10-20T12:30:55.000Z Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027 https://www.biopharmawatch.com/news/VTGN/vistagen-gatc-health-predictive-ai-collaboration BiopharmaWatch en 2026-10-20T12:30:54.000Z Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs https://www.biopharmawatch.com/news/COCH/envoy-medical-six-month-milestone-acclaim-implant BiopharmaWatch en 2026-10-20T12:30:00.000Z Envoy Medical Hits Six-Month Milestone, Marks Halfway Point in Final Stage of Data Collection, and Highlights Differentiated Device Design https://www.biopharmawatch.com/news/NBIX/neurocrine-phase-2-study-nbi-567-alzheimers BiopharmaWatch en 2026-10-20T12:30:00.000Z Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease https://www.biopharmawatch.com/news/RCUS/arcus-casdatifan-kidney-cancer-opportunity BiopharmaWatch en 2026-10-20T12:30:00.000Z Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer https://www.biopharmawatch.com/news/WGS/genedx-expands-diagnostic-leadership-long-read-sequencing BiopharmaWatch en 2026-10-20T12:30:00.000Z GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis https://www.biopharmawatch.com/news/MYGN/myriad-genetics-labcorp-prenatal-health-sale BiopharmaWatch en 2026-10-20T12:30:00.000Z Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp https://www.biopharmawatch.com/news/OPTH/optimi-health-mdma-production-phase-3-ptsd-trial BiopharmaWatch en 2026-10-20T12:30:00.000Z Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-appoints-craig-blanchette-svp-research BiopharmaWatch en 2026-10-20T12:30:00.000Z Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA) https://www.biopharmawatch.com/news/FRNM/freenome-launches-simplescreen-lung-cancer-test BiopharmaWatch en 2026-10-20T12:30:00.000Z Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option https://www.biopharmawatch.com/news/MBOT/microbot-medical-new-patents-global-ip-portfolio BiopharmaWatch en 2026-10-20T12:30:00.000Z Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q3-2026-financial-results BiopharmaWatch en 2026-10-20T12:30:00.000Z Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026 https://www.biopharmawatch.com/news/MBRX/moleculin-ceo-corner-annamycin-miracle-trial-progress BiopharmaWatch en 2026-10-20T12:12:30.000Z Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial https://www.biopharmawatch.com/news/PALI/palisade-bio-presents-pali-2108-results-ueg-week-2026 BiopharmaWatch en 2026-10-20T12:05:00.000Z Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026 https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-q3-2026-results-report BiopharmaWatch en 2026-10-20T12:05:00.000Z Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/WAT/waters-quest-diagnostics-hpv-screening-access BiopharmaWatch en 2026-10-20T12:00:00.000Z Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-unveils-atnm-400-data-eanm-2026-first-human BiopharmaWatch en 2026-10-20T12:00:00.000Z Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer https://www.biopharmawatch.com/news/SRRK/scholar-rock-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-20T12:00:00.000Z Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/RVTY/revvity-launches-signals-labgistics-solution BiopharmaWatch en 2026-10-20T12:00:00.000Z Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows https://www.biopharmawatch.com/news/SNY/duvakitug-phase-2b-results-ueg-week-2026 BiopharmaWatch en 2026-10-20T12:00:00.000Z UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-q3-2026-results-webcast BiopharmaWatch en 2026-10-20T12:00:00.000Z Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026 https://www.biopharmawatch.com/news/BIVI/biovie-bezisterim-parkinsons-disease-ana-2026 BiopharmaWatch en 2026-10-20T12:00:00.000Z BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting https://www.biopharmawatch.com/news/SLDB/solid-biosciences-research-esgct-2026 BiopharmaWatch en 2026-10-20T12:00:00.000Z Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026 https://www.biopharmawatch.com/news/INNV/innovage-fiscal-q1-2027-results-conference-call BiopharmaWatch en 2026-10-20T12:00:00.000Z InnovAge to Announce Fiscal First Quarter 2027 Financial Results and Host Conference Call Tuesday, November 3, 2026 https://www.biopharmawatch.com/news/VERA/vera-therapeutics-asn-kidney-week-webcast BiopharmaWatch en 2026-10-20T12:00:00.000Z Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast https://www.biopharmawatch.com/news/RVMD/revolution-medicines-phase-3-trial-zoldonrasib BiopharmaWatch en 2026-10-20T12:00:00.000Z Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-appoints-new-board-members BiopharmaWatch en 2026-10-20T12:00:00.000Z PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors https://www.biopharmawatch.com/news/YDES/yd-bio-eg-biomed-joiiup-ai-cancer-risk-assessment BiopharmaWatch en 2026-10-20T12:00:00.000Z YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs https://www.biopharmawatch.com/news/ICCM/icecure-enrolls-first-patients-choicestudy BiopharmaWatch en 2026-10-20T11:55:00.000Z IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites https://www.biopharmawatch.com/news/JNJ/johnson-johnson-shockwave-c2-aero-fly-launch BiopharmaWatch en 2026-10-20T11:45:00.000Z Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half https://www.biopharmawatch.com/news/STXS/stereotaxis-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-20T11:40:00.000Z Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-eanm-2026-results-atnm-400 BiopharmaWatch en 2026-10-20T11:30:00.000Z Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models https://www.biopharmawatch.com/news/NGNE/neurogene-ngn-401-rett-syndrome-esgct-congress BiopharmaWatch en 2026-10-20T11:30:00.000Z Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-q3-2026-financial-results-call BiopharmaWatch en 2026-10-20T11:30:00.000Z Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call https://www.biopharmawatch.com/news/ARDX/ardelyx-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-20T11:30:00.000Z Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/NBP/visara-acquires-yol104-2-ossn BiopharmaWatch en 2026-10-20T11:00:00.000Z Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia https://www.biopharmawatch.com/news/UTHR/united-therapeutics-expands-xenograft-production-facility BiopharmaWatch en 2026-10-20T11:00:00.000Z United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-phase-2a-od-001-results BiopharmaWatch en 2026-10-20T11:00:00.000Z Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026 https://www.biopharmawatch.com/news/ACON/aclarion-ceo-shareholder-letter-q3-2026 BiopharmaWatch en 2026-10-20T11:00:00.000Z Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026 https://www.biopharmawatch.com/news/MD/pediatrix-medical-group-2026-q3-conference-call BiopharmaWatch en 2026-10-20T10:45:00.000Z Pediatrix Medical Group 2026 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 29, 2026 https://www.biopharmawatch.com/news/BNTX/biontech-q3-2026-financial-results-update BiopharmaWatch en 2026-10-20T10:45:00.000Z BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026 https://www.biopharmawatch.com/news/HSIC/henry-schein-q3-2026-conference-call-webcast BiopharmaWatch en 2026-10-20T10:30:00.000Z Henry Schein to Webcast Third Quarter 2026 Conference Call on Tuesday, November 3, 2026, at 8:00 a.m. ET https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-publishes-paper-qrx003-netherton-syndrome BiopharmaWatch en 2026-10-20T10:30:00.000Z Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy https://www.biopharmawatch.com/news/PSNL/personalis-resistance-mutation-tracking-next-personal-mrd-test BiopharmaWatch en 2026-10-20T10:00:00.000Z Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-phase-2-trial-results-rap-219 BiopharmaWatch en 2026-10-20T10:00:00.000Z Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania https://www.biopharmawatch.com/news/ALVO/alvotech-fda-approval-simlandi-manufacturing-process BiopharmaWatch en 2026-10-20T08:30:00.000Z Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch https://www.biopharmawatch.com/news/OCS/oculis-phase-2-acuity-trial-privosegtor-presentation BiopharmaWatch en 2026-10-20T06:00:00.000Z Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting https://www.biopharmawatch.com/news/IPHA/innate-pharma-conference-call-q3-2026-update BiopharmaWatch en 2026-10-20T05:00:00.000Z Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update https://www.biopharmawatch.com/news/INSM/insmed-appoints-new-directors-board BiopharmaWatch en 2026-10-20T00:00:00.000Z Insmed Appoints Two New Directors to Its Board https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-acquisition-sod-sciences BiopharmaWatch en 2026-10-19T21:01:00.000Z Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel https://www.biopharmawatch.com/news/ATEC/atec-third-quarter-2026-financial-results-webcast BiopharmaWatch en 2026-10-19T20:35:00.000Z ATEC to Report Third Quarter 2026 Financial Results on October 29, 2026 https://www.biopharmawatch.com/news/HAE/haemonetics-fda-approval-perqseal-elite-system BiopharmaWatch en 2026-10-19T20:15:00.000Z Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-third-quarter-results-november-2026 BiopharmaWatch en 2026-10-19T20:15:00.000Z Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-obesityweek-2026-presentations BiopharmaWatch en 2026-10-19T20:13:00.000Z Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026 https://www.biopharmawatch.com/news/SIBN/si-bone-q3-2026-financial-results-report BiopharmaWatch en 2026-10-19T20:09:00.000Z SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/WGS/genedx-advances-genomic-medicine-ashg-2026 BiopharmaWatch en 2026-10-19T20:05:00.000Z GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026 https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-ifetroban-dmd-update BiopharmaWatch en 2026-10-19T20:05:00.000Z CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM https://www.biopharmawatch.com/news/IART/integra-completes-refinancing-transactions BiopharmaWatch en 2026-10-19T20:05:00.000Z Integra Announces Completion of Refinancing Transactions https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-cfo-transition BiopharmaWatch en 2026-10-19T20:05:00.000Z CRISPR Therapeutics Announces Chief Financial Officer Transition https://www.biopharmawatch.com/news/FTRE/fortrea-acquisition-early-phase-services BiopharmaWatch en 2026-10-19T20:05:00.000Z Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-board-appointments BiopharmaWatch en 2026-10-19T20:05:00.000Z Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-esmo-congress-2026-presentation BiopharmaWatch en 2026-10-19T20:05:00.000Z Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 https://www.biopharmawatch.com/news/SOLV/solventum-fda-clearance-restrata-vac-therapy BiopharmaWatch en 2026-10-19T20:05:00.000Z Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy* https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-appoints-geno-germano-board BiopharmaWatch en 2026-10-19T20:05:00.000Z Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors https://www.biopharmawatch.com/news/CERS/cerus-corporation-q3-2026-financial-results-release BiopharmaWatch en 2026-10-19T20:01:00.000Z Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/DCTH/delcath-systems-esmo-congress-2026 BiopharmaWatch en 2026-10-19T20:01:00.000Z Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma https://www.biopharmawatch.com/news/IRON/disc-medicine-350-million-offering BiopharmaWatch en 2026-10-19T20:01:00.000Z Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/HTFL/heartflow-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-19T20:01:00.000Z Heartflow to Report Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261019 BiopharmaWatch en 2026-10-19T20:01:00.000Z Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CTY/city-therapeutics-ipo-230-million BiopharmaWatch en 2026-10-19T20:01:00.000Z City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares https://www.biopharmawatch.com/news/CYTK/cytokinetics-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-10-19T20:00:00.000Z Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-third-quarter-results-october-2026 BiopharmaWatch en 2026-10-19T20:00:00.000Z Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026 https://www.biopharmawatch.com/news/ANAB/jemperli-approval-msi-h-dmmr-rectal-cancer BiopharmaWatch en 2026-10-19T18:18:00.000Z Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer https://www.biopharmawatch.com/news/ASTH/alignment-health-plan-asth-partner-expand-access-care BiopharmaWatch en 2026-10-19T15:00:00.000Z Alignment Health Plan and Astrana Health Partner to Expand Access to Trusted Local Care for California Seniors https://www.biopharmawatch.com/news/SNY/sanofi-2026-ispe-facility-of-the-year-award BiopharmaWatch en 2026-10-19T14:03:00.000Z ISPE Names Sanofi S.A. the 2026 ISPE Facility of the Year Awards (FOYA) Overall Winner for its Modulus Project https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-renmark-roadshow-october-2026 BiopharmaWatch en 2026-10-19T13:54:27.000Z Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series